Summary:
The Chinese company, founded in July 2020, takes development of medicine-equipment combination products as its core business. It has independently developed medical needle injection systems which can be widely appplied. It is now expanding its overseas market, and hopes to collaborate with foreign potential sales partners under agency or distribution agreement.
Description:
The Chinese company was founded in July, 2020 and is based in Shenzhen of Guangdong province. Since its founding, it has been dedicated to development of medicine-equipment combination products. It has a technical team composed of professionals with rich experience in drug-delivery device design and production. Besides, the company has an operation consultant team of executives of listed companies or from any of the Fortune 500 companies.
The company has developed medical needle injection systems independently. The products are widely applied to insulin, auxin and other peptide products. Such products include disposable injection pens, reusable injection pens, boosters, emergency pens and other series, and have entered the commercial stage. The company will continue to pursue in the field of micro drug delivery, and to be committed to providing personalized and customized products and drug-delivery solutions for pharmaceutical enterprises.
The Chinese company is looking to explore foreign markets with those foreign potential business partners through agency or distribution agreement. European businesses with client base among healthcare industry product and service providers (hospitals, pharmaceutical producers, etc.) and relevant marketing expertise in this regard will be the most ideal. For potential partners without warehousing facilities, an agency agreement will be more suitable, while the distribution agreement will be more suitable for those with warehousing capabilities to run an inventory.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
The Chinese company is looking for partnership with foreign potential business partners through agency or distribution agreement. Those European businesses with client base among healthcare industry product and service providers (hospitals, pharmaceutical producers, etc.) and relevant marketing expertise in this regard will be the most ideal. Potential partners with warehousing facilities and who eye on quick delivery to their own clients are suggested to consider a distribution agreement. An agency agreement will be more suitable for those potential partners who have no physical venue or will to manage an inventory themselves.
IPR Status:
Patents granted
External code:
BOCN20210705001
